×

RNS Number : 1121D

First Derivatives PLC

17 February 2020

 

17 February 2020

 

First Derivatives plc

("FD" or the "Group")

 

Major oilfield services contract win

 

FD (AIM: FDP.L, ESM: FDP.I) announces that it has been selected by a leading global oilfield services company for the use of Kx technology to provide operational intelligence for their customers' oil and gas field assets. This contract, awarded after a thorough technology evaluation by the client, extends the range of Kx use cases within the energy market and showcases the ability of Kx to deliver actionable insights at the edge.

 

 

The flexibility and open nature of the Kx platform will enable new processes and data-intensive analytics to be added as required both in the field and centrally.

 

Using Kx technology to deliver big data levels of analytic capability to the edge, where compute resources are limited, will enable the client to increase efficiency. This represents a new use case for Kx, which the client expects to generate a high return on investment and should be of interest across the broader energy and industrial IoT markets.

 

Seamus Keating, Chief Executive Officer, FD commented: "Making decisions at the time and place where action is required can deliver major operational efficiencies. We believe Kx is the only technology capable of delivering this solution, enabling decision-making in real-time on vast volumes of data. As organisations increasingly look to drive action, not just reports from the data they generate, Kx stands out for its high performance and ability to operate at the edge."

 

 

Enquiries

For further information please contact:

 

First Derivatives plc Seamus Keating, Chief Executive Officer Graham Ferguson, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44(0)28 3025 2242 www.firstderivatives.com
Investec Bank plc (Nominated Adviser and Broker) Andrew Pinder Carlton Nelson Sebastian Lawrence	+44 (0)20 7597 5970
Goodbody (Euronext Growth Adviser and Broker) David Kearney Don Harrington Finbarr Griffin	+353 1 667 0420
FTI Consulting Matt Dixon Dwight Burden Darius Alexander	+44 (0)20 3727 1000

About FD

FD is a global technology provider with more than 20 years of experience working with some of the world's largest finance, technology, automotive, utility, manufacturing and energy institutions. The Group's Kx technology, incorporating the kdb+ time-series database, is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. Kx delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications across multiple industries. FD operates from 15 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 2,400 people worldwide.

 

For further information, please visit www.firstderivatives.com and www.kx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTFLFIRFIISLII

Close

×

Neville Registrars is delighted to welcome Progility Limited as the newest addition to its list of client companies.

Progility provides professional business solutions to global organisations and consumers in order to develop the best project management eco-system possible

Further information can be found on the Company's website: https://www.progility.com/

Close

×

Neville Registrars is delighted to welcome Seagray Group Limited as the newest addition to its list of client companies.

 

Close

×

RNS Number : 6622B

Pennant International Group PLC

03 February 2020

 

                                                                                                                                                           

FOR IMMEDIATE RELEASE                                                                                          3 February 2020          

PENNANT INTERNATIONAL GROUP PLC

 

Contract Wins

 

Pennant International Group plc ("Pennant", the "Group", or the "Company"), the AIM quoted supplier of integrated training and support solutions, products and services which train and assist operators and maintainers in the defence and regulated civilian sectors, is pleased to announce that it has been awarded two new contracts.

 

Australia

 

Pennant Australasia Pty Ltd (the Group's wholly-owned Australian subsidiary) has been awarded a contract for the supply of Pennant training aids and associated services for aviation technician training for the Australian Defence Force at a new training facility in Nowra, Australia.

 

The contract has been awarded by Air Affairs Australia Pty Limited, and is Pennant's second contract in region for training aids. The support services element forms part of the Group's long term strategy to generate an increasing proportion of its revenues from services, particularly services which are both complementary to its product range and relevant to the sectors within which it already operates.

 

The contract is to be delivered over 2020 and 2021 (as an initial phase). The contract value is commercially confidential.

 

Middle East

 

Just prior to year-end, the Group received an order valued at circa £1.5 million for the provision of additional training aids to the Middle East. The order includes two new training solutions, including a 'crew escape trainer', which have been created under the Group's product development strategy and will form part of the Group's range of generic training aids.

 

The contract is 'engineered-to-order' and the majority of revenues will be recognised in 2020 (being supportive of current market expectations).

 

The Group anticipates receiving further orders from this long-standing customer during the year.

 

 

 

Phil Walker (Group CEO) commented: "These exciting new contracts demonstrate not only the increasing diversity of our product and services portfolios but also the Group's continued ability to win business internationally. They will also help to underpin the Group's 2020 financial performance."

 

 

Enquiries:

 

Pennant International Group plc	www.pennantplc.co.uk
Philip Walker, CEO David Clements, Commercial & Risk Director	+44 (0) 1452 714 914
WH Ireland Limited (Nomad and Broker)	www.whirelandcb.com
Mike Coe Chris Savidge	+44 (0) 117 945 3470
Walbrook PR (Financial PR)	[email protected]
Paul Vann Tom Cooper	+44 (0)20 7933 8780 Mob: +44 (0)7768 807631

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTUUSARRNUURUR

Close

×

Neville Registrars are delighted to welcome Seagray Group Limited as the newest addition to its list of client companies.

Seagray Group develops, acquires and licences software and seeks opportunities to trade in markets utilising this technology.

Further information can be found on the Company’s website: https://seagray.com/

Close

×

RNS Number : 5499B

Sativa Group PLC

31 January 2020

 

Press Release

31st January 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Sativa Group Plc

 

("Sativa" or "the Company" or "the Group")

 

Goodbody Botanicals signs deal with Alliance Healthcare

for product distribution to UK Pharmacies

 

Sativa Group Plc subsidiary Goodbody Botanicals has secured a product listing agreement with Alliance Healthcare ("Alliance"), one of the leading distributors and wholesalers of pharmaceutical, medical and healthcare products in the UK and Europe.  This gives Alliance's 10,000+ high street retailer customers access to the Goodbody Botanicals range of market-leading CBD products.  Alliance Healthcare services independent pharmacies, national accounts, and superstores. 

 

In addition, Alliance's syndicated pharmacy salesforce, Skills in Healthcare, has been contracted to promote and sell the Goodbody Botanicals range to the 1,500 top performing independent pharmacy customers.  

 

Sativa Chief Executive Henry Lees-Buckley said: "The Alliance distribution agreement is a significant step in Sativa's Goodbody Botanicals CBD Wellness brand's objective to grow market share with high street pharmacies, grocers, and superstores." 

 

Media enquiries. 

Abchurch Communications Julian Bosdet +44 (0)207 4594 4070  +44 (0) 7771 663 886

[email protected] www.abchurch-group.com

 

For further information please contact: 

 

Henry Lees-Buckley  Chief Executive Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected] www.sativagroup.co.uk	Joseph Colliver Chief Financial Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected]  www.sativagroup.co.uk
NEX Exchange Corporate Adviser   Corporate Finance  Stephen Keys / Max Gould  Cenkos Securities plc  +44 (0) 20 7397 8900	Equity Sales  Julian Morse Cenkos Securities +44 (0) 20 7397 8900

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXUARBRRWUAORR

Close

×

Neville Registrars is delighted to welcome Eco Hotels UK Plc as the newest addition to its list of client companies.

 

Eco Hotels is an owner, developer and asset manager of The Eco™ and The Ecolodge™, three star premium and two star value brands.

 

Further information can be found on the Company's website: https://ecohotelsglobal.com/

Close

×

RNS Number : 2156B

N4 Pharma PLC

29 January 2020

 

29 January 2020

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Update on Nuvec® process improvements

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on the progress of its work to improve the dispersion of Nuvec®, details of which were announced in the Company's Interim Results on 18 September 2019.

 

The first two stages of phase one of the in vitro work have now been completed. The Company has manufactured a new batch of Nuvec® using an improved process and has successfully demonstrated that the Nuvec® particle can be effectively and repeatedly dispersed into a more monodisperse formulation, prior to the addition of DNA. The Company expects that this more monodisperse formulation will result in a more even distribution of DNA across the Nuvec® nanoparticles, thereby resulting in a more monodisperse formulation of DNA loaded Nuvec®.

 

A number of techniques are available to measure particle size distribution, including dynamic light scattering, laser diffraction and transmission electron microscopy (TEM). The Company has compared these nanoparticle measurement techniques to ensure a full understanding of the extent of agglomeration of Nuvec®. N4 Pharma's analysis of these techniques has confirmed that TEM provides a robust assessment of the size and morphology of individual nanoparticles and that laser diffraction is a more suitable and consistent process to measure Nuvec® dispersion in an aqueous solution and to define the extent of agglomeration. Using TEM and laser diffraction the Company has been able to more accurately measure the size of individual nanoparticles and quantify the levels of dispersion seen for Nuvec®.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"The work highlighted in the Interim Results is moving forward well and we are pleased to have been able to produce a more disperse form of Nuvec® prior to the addition of DNA.

 

We will now move forward with the next stage of the work to investigate how to add DNA to this new more disperse Nuvec® in order to maintain this improved level of dispersion prior to injection.

 

We very much appreciate the support of our shareholders as we undertake this process improvement work and will provide further updates in due course."

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: +44(0)203 328 5656
Scott PR Georgia Smith	Tel: +44(0)1477 539 539

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

RESBPMRTMTJTBAM

Close

×

RNS Number : 9495Z

Elecosoft PLC

16 January 2020

 

Elecosoft Plc

("Elecosoft" or the "Company") 

Launch of its new Artificial Intelligence visualisation tool

Elecosoft (AIM: ELCO), announces the launch of its new Artificial Intelligence ("AI") software tools at the Domotex Show in Hanover in January 2020. The new AI visualisation tools are for use in the interior flooring and materials décor markets and were very well received by customers of Elecosoft's ESIGN GmbH ("ESIGN") and Active Online GmbH ("Active Online") visualisation subsidiaries which are active in these markets worldwide.  

John Ketteley, Executive Chairman of Elecosoft, commented:

"Elecosoft's new AI visualisation tool enable consumers and professional interior designers alike to use any photo, taken from a camera, smartphone or handheld device to visualise flooring options in real-time from manufacturers stock libraries.  There is no longer the need to manually treat photographs as our AI technology automatically identifies the floor area, plane, scale, reflections and shadows.

In our opinion, the AI visualisation tool enables consumers to make confident decisions when replacing their existing flooring, and in turn represents a significant value add for our B2B clients by improving their sales conversion rates. 

The AI visualisation tool itself can also be integrated directly to Elecosoft's Interiormarket and Materialo® visualisation and product information management platforms; and can also be integrated into online stores and e-commerce platforms."

**ENDS**

For further information, please contact:

Elecosoft plc                          Tel: +44 (0)20 7422 8000

JHB Ketteley, Executive Chairman

Jonathan Hunter, Chief Operating Officer

Ben Moralee, Finance Director

finnCap Ltd                           Tel: +44 (0)20 7220 0500

Geoff Nash / Kate Washington (Corporate Finance)

Camille Gochez (Corporate Broking)

Newgate Communications Tel: +44 (0)20 3757 6880

Elisabeth Cowell / Isabelle Smurfit

 

About Elecosoft plc

Elecosoft is a specialist international provider of software and related services to the Architectural, Engineering, Construction and Owner-Operator industries and digital marketing industries from centres of excellence in the UK, Sweden, Germany and the US. Elecosoft's market leading software solutions are developed by teams in the United Kingdom, Sweden and Germany; and its software solutions cover project management, construction site management, estimating, timber engineering, 3D design and visualisation, and cloud based digital marketing solutions. Elecosoft is listed on the Alternative Investment Market in London (AIM: ELCO).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAGPURWGUPUGMA

Close

×

RNS Number : 0622Z

Midatech Pharma PLC

08 January 2020

 

8 January 2020

 

Midatech Pharma PLC

 

("Midatech" or the "Company")

 

Positive Results from MTD201-102 Study Support Subcutaneous Route for Long-Acting Octreotide Product

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce positive headline results from Study 102.  The study met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.

 

The results demonstrate that MTD201 can deliver sustained plasma octreotide concentrations within the range needed for therapeutic efficacy with an injection interval of six to eight weeks by either subcutaneous or intramuscular administration.

 

These are key advantages for patients, payors and physicians over the current standard of care.  The subcutaneous route of administration is simpler, less painful, and allows the potential for self-administration at home, with less need for hospital visits or nurse supervision to receive treatment.  An extended dose interval would reduce the annual treatment burden for patients from 12 to just 6 injections per year, thus providing a much less frequent, more cost effective and patient friendly treatment regimen.  These attributes are in addition to already demonstrated advantages for MTD201, including less painful injections due to smaller needle size (21 gauge needle, compared to 19/18 gauge for SLAR), simpler, more reliable reconstitution and injection (less than 10 minutes versus up to 40 minutes for SLAR), and flexibility for unit doses above 30mg.

 

Study 102 investigated the subcutaneous administration of MTD201 as an additional alternative injection route to intramuscular administration, and determined the preferred administration route to take forward into the MTD201 registration study to be commenced in mid 2020.  The primary endpoints were to determine the relative plasma octreotide bioavailability and pharmacokinetics of MTD201 deep subcutaneous injection, MTD201 deep intramuscular injection and Sandostatin® Octreotide Acetate Injection deep subcutaneous injection.  The study was conducted in 28 healthy subjects and following a single injection of MTD201 (either subcutaneously or intramuscularly) in early October 2019, all subjects entered a 63-day observation and sampling period to determine plasma octreotide and insulin-like growth factor-1 (IGF-1) concentrations. 

 

The key preliminary results from Study 102 include:

·    Pharmacokinetics ("PK")

o both subcutaneous and intramuscular injections produced a similar overall extended octreotide PK profile

o  the octreotide release profile supports injection intervals of up to eight weeks, compared to the predominantly 4 weekly current standard of care

o inter-subject variability for MTD201 was consistent with that observed for currently commercialised long-acting octreotide products

·    Pharmacodynamics ("PD")

o  sustained reduction in plasma IGF-1 throughout the 63-day assessment period was similar for both subcutaneous and intramuscular injections

·    Safety

o  MTD201 was very well tolerated.  Results show that adverse events were similar for both subcutaneous and intramuscular injections.  There were only minor and transient injection site reactions with no differences between the injection routes

 

Preparation for commencement of the next pivotal study for the clinical development for MTD201 is now underway, which is planned to commence later in H1 2020.  A pivotal registration programme to support a second indication in NET is also expected to commence in 2020.

 

Commenting Craig Cook, CEO of Midatech, said: "We are very pleased with the positive results of Study 102.  It confirmed both the subcutaneous dosing route for MTD201, as well as the potential for extended dosing intervals.  These are key advantages for patients, physicians and payors, being the first therapy to offer this, and also gives Midatech a competitive advantage versus others as we move the product through to potential approval."

 

For more information, please contact:

Midatech Pharma PLC

Dr Craig Cook, CEO Stephen Stamp, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: [email protected]

Edison Group (US Investor Relations) Joseph Green/ Laine Yonker (646) 653-7030/ 7035 [email protected]/ [email protected]

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

 

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 

·    Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

·    MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

·    MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

 

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

 

Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the potential treatment options for MTD201 and the development of the programme.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

RESEAPFXESKEEFA

Close